A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United States. Across both regions, oncologists have widely reported they have prescribed biosimilars, and with an increasing number of biosimilars submitted for approval, alongside pressures from payers and institutions to lower costs, the use of biosimilars is likely to increase. The absence of ESA biosimilars in the United States and of monoclonal antibody biosimilars for oncology across both regions presents opportunities for biosimilar manufacturers as well as considerations for companies wishing to defend against biosimilar erosion. We conducted market research with medical oncologists and hematology-oncologists in France, Germany, and the United States to gain insights on attitudes toward biosimilars, drivers and barriers to biosimilar use, and expectations for future adoption.


Related Reports

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details

Biosimilars - Current Treatment - Oncology

In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launch...

View Details

Biosimilars - Current Treatment - Biosimilar Target Product Profiles (Oncology)

To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists

View Details

Biosimilars - Market Events And Forecast - Oncology

In 2018, sales of branded monoclonal antibody biologics in oncology exceeded $20 billion across the major markets (United States, EU5, and Jap...

View Details